New drug combo aims to boost lymphoma treatment

NCT ID NCT07588698

First seen May 17, 2026 · Last updated May 17, 2026

Summary

This study tests a new drug, epcoritamab, added to standard chemotherapy (R-CHOP) for people newly diagnosed with an aggressive form of B-cell lymphoma. The main goal is to check for a specific side effect called cytokine release syndrome. About 20 adults will take part in this early-phase trial to see if the combination is safe and tolerable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA NON-HODGKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zuckerberg San Francisco General

    San Francisco, California, 94110, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.